Shah Capital nominates two highly qualified independent director candidates for Novavax
15 avr. 2024 06h00 HE
|
Shah Capital
Believes the two new nominated directors possess the necessary experience to tackle the underperformance of the business which will improve its share price Shah Capital which owns 6.7% of...
Vaccine Adjuvant Market is estimated to be US$ 2.0 billion by 2032; Rising Prevalence of Infectious Diseases to Fuel the Market Growth - By PMI
25 sept. 2023 14h00 HE
|
PMI
Covina, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Market overview: Adjuvant is formulated as a part of vaccine to induce protection against infection in human beings. Adjuvant has become an important...
FFF Enterprises Inc. Adds COVID-19 Vaccines and Respiratory Syncytial Virus (RSV) Products to Its Comprehensive, Expanding Portfolio
13 sept. 2023 13h34 HE
|
FFF Enterprises.com
TEMECULA, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- FFF Enterprises Inc., recognized as the nation's most trusted specialty drug distributor and diversified healthcare company, has partnered with...
Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate
24 juil. 2023 08h30 HE
|
Dyadic International, Inc.
Dosing of patients completed at the end of FebruaryData Safety Monitoring Board conducted analysis of Day 29 data No major vaccine-related safety concerns for either of the two dose levelsNo Serious...
Dyadic Reports Second Quarter 2022 Financial Results and Highlights Recent Company Developments
10 août 2022 16h00 HE
|
Dyadic International, Inc.
Submission of a Clinical Trial Application (CTA) with South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 study to support clinical safety of proteins produced from...
Dyadic to Participate in Bio-Manufacturing Innovation Summit and NIIMBL National Meeting
05 juil. 2022 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., July 05, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and...
Dyadic Announces Successful Toxicology Data Published in “Toxicologic Pathology”
09 mai 2022 08h30 HE
|
Dyadic International, Inc.
Toxicology data published in the international peer-reviewed scientific journal “Toxicologic Pathology” demonstrates excellent safety profile and lasting immunogenic response from Dyadic’s DYAI-100,...
DEADLINE ALERT for SNAP, and NVAX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
10 janv. 2022 11h18 HE
|
The Law Offices of Frank R. Cruz
LOS ANGELES, Jan. 10, 2022 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Snap, Novavax, Zillow, and Ginkgo Bioworks and Encourages Investors to Contact the Firm
04 janv. 2022 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
DEADLINE ALERT for ONTF, SNAP, and NVAX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
03 janv. 2022 11h27 HE
|
The Law Offices of Frank R. Cruz
LOS ANGELES, Jan. 03, 2022 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...